Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned 2023-05-08
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
Source: pr-inside.com
Page 18 - Lexaria Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lexaria Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lexaria Bioscience Today - Breaking & Trending Today
Short Interest in Lexaria Bioscience Corp. (NASDAQ:LEXX) Drops By 6.1%
Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Rating) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 317,900 shares, a decline of 6.1% from the March 31st total of 338,500 shares. Based on an average daily volume of 20,800 shares, the […]
Source: theenterpriseleader.com
Lexaria Bioscience : Corporate Highlight Sheet
LEXARIA BIOSCIENCE CORP. NASDAQ: LEXX INVESTOR CONTACT Phone: 250-765-6424 ext. 202... | May 1, 2023
Source: marketscreener.com
Lexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hypertensionCalifornia-based InClin to provide CRO services to manage and expedite
Source: finanznachrichten.de
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension ...
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension ...
Source: pr-inside.com